Summary: A national audit of 781 early syphilis cases presenting during 2002-03 in UK genitourinary medicine clinics was conducted in late 2004, organized through the Regional Audit Groups. Data were aggregated by region and National Health Service trust, allowing practice to be compared between regions, between trusts within regions, as well as to national averages and the UK National Guidelines. An enzyme immunoassay was used to diagnose 695 (89%) cases (regional range 18-100%). Use of a non-treponemal test was not recorded for 44 (6%) cases. Dark ground microscopy was used in the diagnosis of only 80 (29%) primary cases. Uptake of HIV testing was 77% (range 69-94%). Nationally, 527 (67%) treatments were parenteral, with almost equal use of benzathine penicillin G for 262 (50%, range 0-97%) cases and procaine penicillin G (PPG) for 260 cases (49%, range 3-100%). There were 14 (5%) treatments with less than the recommended 750 mg dose of PPG. One hundred and five (40%) PPG treatments were with greater than 750 mg and/or for longer than 10 days of which 76 (72%) were for early latent syphilis and/or cases with HIV infection. One hundred and ninety two (86%, range 0-100%) of all oral treatments were with doxycycline. The recommended regimen of 100 mg doxycycline twice daily for 14 days was used for 104 (53%) cases; the other 91 (47%) treatments were with a variety of regimens, mainly treatments with larger doses and/or longer treatment intervals and some combination treatments. Fourteen (2%) cases were not treated; treatment was not reported for seven (0.9%) and not known for 10 (1.3%) cases, who were treated at other centres.
Introduction
In view of recent outbreaks of infectious syphilis in the UK, 1 the National Audit Group (NAG) of the British Association for Sexual Health and HIV (BASHH) undertook an audit of early syphilis management in the UK in late 2004.
Objectives and goal
The objectives were to provide data to allow comparison of practice against national standards and guidelines, and against average UK performances, as well as to allow comparisons between regions and between trusts within regions. The goal of the audit was to improve the management of early syphilis in the UK.
finding was based on diagnostic codes A1, A2 or A3 of the statutory KC60 and ISD(D)5 returns. 4 The number of cases suggested was: single doctor clinic -first 10 cases; two doctors -first 20 cases; larger centres -first 30 cases during the audit interval. The following process was used to collect data. The audit questionnaires were translated into an electronic form that was emailed to Regional Chairs in the form of a Microsoft Access database. The paper questionnaires were sent to clinics in regions by the Regional Chairs; pseudonymized data were collected by clinics on the paper questionnaires and returned to Regional Chairs. The databases were populated by the offices of Regional Chairs from the completed paper questionnaires and returned by email to a central office. These data were returned during September-December 2004, and collated and aggregated by region and by NHS trusts/clinics within regions.
This paper reports on data obtained from the case notes part of the audit with regards to demographic features of the sample, as well as performance data in terms of national and regional averages, and regional ranges, relating to the use of diagnostic tests and treatments. Data aggregated by regions is available on the BASHH website and allows comparisons to be made between regions. Data aggregated by NHS trusts within regions has been provided to Chairs of Regional Audit Groups to allow service comparisons between trusts.
Results

Sampling and demography
Nationally, 16 of the 17 UK regions participated, contributing a total of 781 cases made up of 702, 49 and 30 cases from England, Scotland and Northern Ireland, respectively. There were a total of 2694 diagnoses of early syphilis reported during the audit interval (personal communications -see acknowledgements), comprising 1941 primary and secondary diagnoses and 671 early latent diagnoses in England, 37 primary and secondary cases and 16 early latent diagnoses in Scotland, and 25 primary and secondary diagnoses and four early latent diagnoses in Northern Ireland. Hence, 27%, 92% and 100% of early syphilis cases in England, Scotland and Northern Ireland, respectively, were sampled. Contribution of cases from the regions ranged from 1% to 15%, and 255 (33%) cases were from within the three London regions. The region outside London with the greater number of cases was the North West with 103 (13%) cases. One hundred and forty four clinics took part in the audit and 107 of these contributed cases.
Nationally, there was even distribution of cases over the age range 26-40 years (419, 54%); 40 (5%) cases were aged o20 years and 71 (9%) cases were aged >50 years. There were 665 (85%, range 67-100%) male cases and 116 (15%, range 0-33%) female cases, of whom 26 (22%, range 0-100%) were pregnant. There was a preponderance of female cases in the South of England with 61 (52%) in South Thames and Anglia. Nationally, 14 (54%) pregnant women were from non-white ethnic groups.
The majority of cases were homosexual men, 465 (60%, range 33-93%), with heterosexual men 164 (21%, range 0-56%), heterosexual women 110 (14%, range 0-33%), bisexual men 33 (4%, range 0-12%); there were three homosexual women, and one bisexual woman, and sexual preference was not known for five cases. The majority were of white ethnic groups, 597 (76%, range 56-100%), with 154 (20%, range 0-40%) from other ethnic groups, comprising: Black 99 (13%, range 0-33%); Asian/ Asian British 40 (5%, range 0-12%); Mixed eight (1%, range 0-3%), and Chinese/Other seven (1%, range 0-2%). The ethnic group was not recorded for 30 cases (4%, range 0-21%). Of 56 Black Caribbean cases, 41 (73%) were in South London, and 23 (58%) of 40 Black African cases were in South London and Anglia.
The following stages of early syphilis were reported: primary 279 (36%, range 0-52%), secondary 250 (32%, range 11-71%), and early latent 247 (32%, range 4-67%). Stage was classified as 'reinfection' for one case and not recorded for four cases. Nationally, 477 (61%, range 33-83%) cases were symptomatic, with 244 (87%, range 67-100%) primary cases, 198 (79%, range 0-100%) secondary cases and 33 (13%, range 0-100%) early latent cases having symptoms. Use of a non-treponemal test was not recorded for 44 (6%) cases. There was highly variable use of DGM between regions, and DGM was positive for around 40% of tests performed. The total of 107 DGMs were performed by 32 (30%) clinics, with 17 clinics performing one test, four clinics two tests, one clinic three tests, two clinics four tests, two clinics five tests, and seven, eight, nine, 10, 13 and 14 tests, one clinic each. Very little use was made either of the polymerase chain reaction (PCR) (17 tests, two positive) or direct fluorescent antibody tests (eight tests, none positive).
Use of diagnostic tests
Six hundred and ninety six (89%) cases were tested for other sexually transmitted infections, and a total of 281 diagnostic codes were recorded for 220 cases, including the following: uncomplicated genital gonorrhoea (52), non-specific urethritis (43), uncomplicated genital chlamydial infection (40), first episode anogenital condylomata (18), first episode anogenital herpes simplex infection (12), viral hepatitis (6), complicated genital infection (2), trichomoniasis (5), antigen positive hepatitis B infection (1) and donovanosis (1). Table 1 shows the uptake of HIV testing; this measure included cases for whom testing was performed as well as 80 (10%, range 0-31%) cases already known to have HIV infection. There were 43 new diagnoses of HIV infection, most of which (32, 74%) affected homosexual or bisexual men, although uptake of HIV testing varied by as much as 25% between regions. Nationally, testing was declined by 130 (17%, range 0-24%) cases, not offered to 16 (2%, range 0-22%) cases, not documented for 24 (3%, range 0-14%) cases and this question was not answered for 9 (1%, range 0-6%) cases.
Treatment
Nationally, parenteral treatment was the first treatment choice for 527 (67%, range 45-100%) cases, with approximately equal use of benzathine penicillin G (BPG) and procaine penicillin G (PPG) (including 11 Bicillin treatments) for 262 (50%, 0-97%) and 260 (49%, 3-100%) cases, respectively (Table 2 ). An oral treatment was the first treatment choice for 223 (28%, range 0-52%) cases (Table 3) , with doxycycline as the only oral treatment comprising 192 (86%, range 50-100%) of oral treatments (Table 4) . Fourteen cases (2%, range 0-6%) were not treated. Ten (2%, range 0-11%) cases were treated by another clinic and treatment was not known, and no report of treatment was received for the remaining 7 (1%, range 0-6%) cases.
Overall, the most common dose of PPG was the 750 mg dose (Table 2) . Sixty-seven (26%) PPG treatments were with doses >750 mg. Of these, only 28 (42%) were treatments for early latent syphilis, and only 27 (40%) were treatments for cases with HIV infection. In 14 (5%) instances treatment was with a dose o750 mg PPG. There were 5 (2%) treatments with long-acting PPG 2 g. The dose used was not clear for 11 (4%) treatments. In one region amoxycillin plus probenecid was used for three cases for weekend treatment to substitute for PPG. Overall, 94 (36%) PPG treatments were for >10 days: 10 (4%) cases were treated for 12 days, 37 (14%) for 14 days, one (0.5%) for 15 days, 39 (15%) for 17 days, two (1%) for 19 days, one (0.5%) for 20 days, four (2%) for 21 days and not specified for seven (3%). Of cases treated for longer than 10 days, only 46 (29%) were treatments for early latent syphilis and only 36 (23%) were treatments for cases with HIV infection. Nationally, 105 (40%) PPG treatments (of cases in 33 clinics in 14 regions) were with greater than 750 mg and/or for longer than 10 days; 49 (47%) of these treatments were for early latent syphilis, 37 (35%) for cases with HIV Of the 204 cases without HIV infection and initially treated with PPG, 142 (70%, range 33-100%) were treated with 750 mg, 39 (19%) with >750 mg, 14 (7%) with o750 mg, one (0.5%) with long-acting PPG, and the dose was not clear for 8 (4%) cases; 144 (71%, range 47-100%) were treated for 10 days, 58 (28%, range 0-53%) for >10 days, duration was not specified for two (1%) and there were no cases treated for o10 days. One hundred and twenty-three cases (60%, range 31-100%) cases were treated with 750 mg PPG and for 10 days.
Overall, doxycycline was used in the initial treatment of 195 (25%) cases, including three treatments combined with azithromycin. The recommended regimen of 100 mg twice daily (bd) for 14 days was used in 104 (53%) cases. However, 91 (47%) treatments were with a variety of other regimens, including treatment with larger doses and/or longer treatment intervals, once daily treatment and some combination treatments. Of these, 75 (82%) bd treatments were with >100 mg bd and/or for longer than 14 days; 33 (44%) of these treatments were for early latent syphilis, 18 (24%) for cases with HIV infection, and 46 (61%) for early latent syphilis and/or cases with HIV infection. The remaining 16 (18%) treatments were with a variety of once daily regimens (Table 4) .
Of 123 cases who also had HIV infection, 88 (72%, range 0-100%) and 31 (25%, range 0-100%) received parenteral and oral treatments, respectively, as treatments of first choice; two (2%) cases were treated elsewhere and treatment was not known, treatment was not recorded for one (1%) case and one (1%) case was not treated. Of the parenteral treatments used to treat cases with HIV infection, 56 (64%) were with PPG, 15 (17%) with two dose of BPG, nine (10%) with one dose of BPG, six (7%) with three doses of BPG, one (1%) with benzyl penicillin G, and one (1%) with ceftriaxone. Of the 56 cases treated with PPG, 21 (38%) were treated with 2 g, 27 (48%) with o2 g, five (9%) with >2 g, and the dose was not clear for three (5%) cases. Of the 56 treatments with PPG, 15 (27%) were for 10 days, two (4%) for 12 days, six (11%) for 14 days, one (2%) for 15 days, 25 (45%) for 17 days, one (2 %) for 19 days, one (2 %) for 21 days, and not stated for five (9%). Only 16 (28%, range 20-71%) cases with HIV infection were treated with 2 g PPG and for 17 days. A total of 27 (22%) cases with HIV infection were treated with doxycycline.
There were 25 (all initial) treatments involving the use of probenecid, 13 of 15 treatments with amoxycillin (87%), and 12 treatments with PPG. Of the latter, five treatments were for early latent syphilis (all of these were with doses >750 mg for 17-21 days), five treatments for secondary syphilis (also with doses >750 mg for 14-24 days), and the remaining two treatments were for primary syphilis, one with 2 g of PPG for 17 days. There were 29 repeat treatments; in three cases re-infection was reported, and no cases of relapse or treatment failure were reported. Eleven initial treatments with PPG were repeated: six with doxycycline treatments, two with erythromycin 500 mg twice daily for 14 days, one with azithromycin 1 g stat, one with two doses of BPG, and the remaining re-treatment was not specified. Nine initial treatments with BPG were repeated: six treatments with doxycycline and three treatments with PPG. Six initial treatments with doxycycline were repeated: three with BPG, two with higher dose doxycycline regimens and one with azithromycin 500 mg PO daily for 10 days. Two initial treatments with a stat dose of azithromycin were each repeated with azithromycin 500 mg once daily for 10 days. One ceftriaxone treatment was repeated with a course of erythromycin treatment.
Nationally, 509 (65%, range 43-100%) treatments were directly observed, but these were nearly all parenteral treatments: 503 of 527 (95%) parenteral treatments were reported as directly observed. The remaining six cases comprised five oral treatments (one for a case with HIV infection) and an unknown treatment.
Advice about adverse drug reactions was received by 516 (66%, range 0-87%) cases. There were a total of 50 (6%, range 0-23%) cases affected by adverse events, comprising 35 (7%) and 15 (7%) cases receiving 527 parenteral and 223 oral treatments, respectively. Fourteen of the oral treatment events were with doxycycline, and one with amoxycillin. The following 50 adverse reactions affecting 48 cases were reported: Jarisch-Herxheimer reaction (12), rash (11), paraesthesia/pain symptoms (6), fever (4), fainting (3), nausea (3), vomiting (3), diarrhoea (2), flu-like symptoms (1), lower limb oedema (1), panic attack (1), procaine reaction (1), pruritis (1), weight loss (1) and three non-specified events; there was no description of the adverse reactions affecting two cases. A course of corticosteroids was prescribed for 33 cases (4%, range 0-14%, in 10 regions). The indications for use of corticosteroids were as follows: specific prevention of the Jarisch-Herxheimer reaction (12), treatment of the Jarisch-Herxheimer reaction (3), prophylactic use (3), treatment of a possible JarischHerxheimer reaction (1), treatment of chorioretinitis (1) and treatment of cranial nerve palsy (1) . In 12 cases no information was presented to explain the use of corticosteroids. Three corticosteroid treatments were during pregnancy -one for possible Jarisch-Herxheimer reaction, and not specified for the other two cases.
Discussion
This is the first UK national audit of early syphilis management, and the first national audit to provide clinical performance data aggregated by regions and NHS trusts. Over one quarter of cases in England and most cases in Scotland and Northern Ireland were sampled. Data has rapidly been disseminated to Chairs of Regional Audit Groups to facilitate comparative and interventional work that might lead to maintaining or improving practice.
The absence of symptoms in some cases of primary and secondary syphilis, reporting of symptoms in some cases of early latent syphilis, as well as use of higher doses and longer durations of PPG regimens, suggests unsatisfactory use of diagnostic codes for case definition. However, it is possible that some treatments of primary syphilis pre-empted, or took place before, the appearance of symptoms (e.g. where epidemiological treatment took place).
The 6 The very low use of the two other main direct detection methods, PCR and direct fluorescent antibody (DFA), probably reflects lack of data about the relative contribution of these tests to earlier and/or increased detection of early syphilis. DGM is relatively easier to provide than PCR and DFA. This audit supports the recommendation of a recent evaluation, 7 clearly showing the usefulness of DGM in the early diagnosis of primary and secondary syphilis and that DGM should be available in all genitourinary medicine clinics.
There was an important number of cases without HIV infection who received treatment doses and/ or durations of PPG and doxycycline greater than those recommended by the CEG guidelines. Treatments in excess of the recommended doxycycline regimen in early syphilis may reflect concern about reported treatment failure with the recommended regimen for doxycycline, 8 treatment modifications because of drug interactions, concern about possible asymptomatic neurosyphilis, or the weak evidence base supporting the currently recommended doxycycline treatment for early syphilis. The once daily treatments with doxycycline may reflect treatment simplification to encourage adherence. Most use of higher doses and longer durations of PPG regimens was found in cases with early latent syphilis or with HIV infection, although 28% of PPG treatments in excess of those recommended by the National Guidelines were for neither early latent syphilis nor HIV infection and might be explained by concern about possible asymptomatic neurosyphilis. By contrast, based on the recommendation in the National Guidelines 2 that cases with HIV infection are treated 'as for neurosyphilis,' there is considerable undertreatment of early syphilis in cases with HIV infection.
Conclusions and suggested areas for practice improvement/intervention
Increased use of pre-treatment non-treponemal tests to 100% is needed in some regions. More use should be made of DGM; training is available in the UK to support increased use of DGM (details available on the BASHH website). HIV infection is particularly important in early syphilis and some regions should consider interventions to improve uptake of HIV testing. More research is needed to determine the role of direct detection methods in early syphilis diagnosis.
There was a considerable amount of treatment in excess of that recommended by the UK National Guidelines for early syphilis management, not all attributable to treatment of cases with HIV infection. This suggests inappropriate use of diagnostic codes or, particularly with regard to doxycycline treatments, lack of confidence among clinicians in the currently recommended treatments. Further work may be needed to improve the definition or appropriate use of the early syphilis diagnostic codes. Alternatively, increased stakeholder involvement in the writing of the UK guidelines for early syphilis management, such as that described in a recent article on guideline development, 9 may improve use of recommended treatments. Based on the National Guidelines, 2 there is considerable under-treatment of early syphilis in cases with HIV infection that may improve with the publication of guidelines on treatment of acquired syphilis in HIV infection. 10 Detailed data, aggregated by region, are available on the BASHH website: http://www.bashh. org/committees/nag/index.htm 
